LifeMD(R) to Offer Market-Leading Pricing for GLP-1 Medications Wegovy(R) and Ozempic(R) in Continued Collaboration with Novo Nordisk
(NasdaqGM:LFMD),(NasdaqGM:LFMDP), NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) — LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services and pharmacy, today announced a new, lower cash-pay price for GLP-1 medications, Wegovy(R) and Ozempic(R), made possible through its ongoing collaboration with Novo Nordisk. LifeMD will now offer the 0.25 mg and 0.5 mg […]